Renal Cell Cancer

• Diverse Delayed Skin Reactions To PD-1 Inhibitor Therapy Revealed
• Germline Mutations Prevalent In Advanced RCC Patients
• Sorafenib–Chemotherapy Tested For Metastatic Renal Collecting Duct Carcinoma
• Systemic treatment of advanced renal cancer
• Perspectives from ASCO 2018: Advances in metastatic RCC, the CARMENA study
• ESMO videos: Perspectives from ASCO 2018
• ASCO 2018: Sunitinib Alone Sufficient For RCC Patients With Limited Metastatic Burden
• Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
• ESMO E-Learning: Next Generation Drugs in Kidney Cancer
• Introduction
• Case presentation: Immunotherapy in kidney metastatic cancer: When?
• Metastatic renal cancer: evidence-based treatment
• First-Line Nivolumab Plus Ipilimumab Supported For Intermediate-, Poor-Risk Advanced RCC
• Early Avelumab Plus Axitinib Findings ‘Encouraging’ For Treatment-Naive Advanced RCC
• ESMO Videos on Genitourinary Cancers: Highlights from ASCO GU 2018
• ASCO GU: Highlights on Renal Cell Cancer: IMmotion151 and Other Combination Studies
• Axitinib–Pembrolizumab ‘Promising’ As Possible First-Line Combination For Advanced RCC
• Participant Clinical Case Discussion: Immunotherapy to the Rescue in Advanced RCC
• Advanced Urinary Cancer (Renal and Bladder)
• Cabozantinib ‘Good Treatment Option’ For RCC Bone Metastases
• The optimal timing of cytoreductive nephrectomy
• Potential biomarkers for decision making
• Expanding knowledge of adjuvant therapy
• Can local ablation delay the use of systemic therapy for oligometastasis - Radiation therapy
• Kidney cancer

• « Previous
• 1
• 2
• ...
• 18
• Next »